Dorsey & Whitney Trust CO LLC Boosts Position in Takeda Pharmaceutical Co. $TAK

Dorsey & Whitney Trust CO LLC raised its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 29.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,140 shares of the company’s stock after buying an additional 4,591 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Takeda Pharmaceutical were worth $299,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in TAK. FNY Investment Advisers LLC purchased a new position in Takeda Pharmaceutical during the 1st quarter valued at about $37,000. Farther Finance Advisors LLC grew its holdings in Takeda Pharmaceutical by 29.2% during the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock valued at $69,000 after buying an additional 1,045 shares in the last quarter. Fifth Third Bancorp grew its holdings in Takeda Pharmaceutical by 85.5% during the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company’s stock valued at $78,000 after buying an additional 2,411 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in Takeda Pharmaceutical during the 4th quarter valued at about $94,000. Finally, GAMMA Investing LLC grew its holdings in Takeda Pharmaceutical by 22.6% during the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock valued at $105,000 after buying an additional 1,296 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Up 1.3%

TAK stock opened at $15.5030 on Friday. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $49.33 billion, a PE ratio of 51.68 and a beta of 0.22. Takeda Pharmaceutical Co. has a twelve month low of $12.80 and a twelve month high of $15.56. The stock has a 50-day simple moving average of $14.80 and a two-hundred day simple moving average of $14.68.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The business had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. On average, equities analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.